Balaji Paul Gajanan, Bhimrao Londhe Sachin, Yadav Awesh K
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli (An Institute of National Importance under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, GOI), A Transit Campus at Bijnor-Sisendi Road, Near CRPF Base Camp, Sarojini Nagar, Lucknow, 226002, Uttar Pradesh, India.
Mol Neurobiol. 2025 Jan;62(1):184-220. doi: 10.1007/s12035-024-04215-3. Epub 2024 Jun 3.
Stroke, a severe medical condition arising from abnormalities in the coagulation-fibrinolysis cycle and metabolic processes, results in brain cell impairment and injury due to blood flow obstruction within the brain. Prompt and efficient therapeutic approaches are imperative to control and preserve brain functions. Conventional stroke medications, including fibrinolytic agents, play a crucial role in facilitating reperfusion to the ischemic brain. However, their clinical efficacy is hampered by short plasma half-lives, limited brain tissue distribution attributed to the blood-brain barrier (BBB), and lack of targeted drug delivery to the ischemic region. To address these challenges, diverse nanomedicine strategies, such as vesicular systems, polymeric nanoparticles, dendrimers, exosomes, inorganic nanoparticles, and biomimetic nanoparticles, have emerged. These platforms enhance drug pharmacokinetics by facilitating targeted drug accumulation at the ischemic site. By leveraging nanocarriers, engineered drug delivery systems hold the potential to overcome challenges associated with conventional stroke medications. This comprehensive review explores the pathophysiological mechanism underlying stroke and BBB disruption in stroke. Additionally, this review investigates the utilization of nanocarriers for current therapeutic and diagnostic interventions in stroke management. By addressing these aspects, the review aims to provide insight into potential strategies for improving stroke treatment and diagnosis through a nanomedicine approach.
中风是一种由凝血-纤溶循环和代谢过程异常引起的严重病症,由于大脑内血流阻塞导致脑细胞受损。迅速而有效的治疗方法对于控制和保护脑功能至关重要。传统的中风药物,包括纤溶药物,在促进缺血性脑再灌注方面起着关键作用。然而,它们的临床疗效受到血浆半衰期短、血脑屏障(BBB)导致的脑组织分布有限以及缺乏向缺血区域的靶向药物递送的阻碍。为应对这些挑战,出现了多种纳米医学策略,如囊泡系统、聚合物纳米颗粒、树枝状大分子、外泌体、无机纳米颗粒和仿生纳米颗粒。这些平台通过促进药物在缺血部位的靶向积累来增强药物的药代动力学。通过利用纳米载体,工程化药物递送系统有潜力克服与传统中风药物相关的挑战。这篇综述探讨了中风的病理生理机制以及中风中血脑屏障的破坏。此外,本综述研究了纳米载体在当前中风管理治疗和诊断干预中的应用。通过探讨这些方面,本综述旨在深入了解通过纳米医学方法改善中风治疗和诊断的潜在策略。